Humanised Bispecific Monoclonal Antibody for Cancer Therapy
Author Information
Author(s): A. Bruynck, G. Seemann, K. Bosslet
Primary Institution: Research Laboratories of Behringwerke AG
Hypothesis
Can a humanised bispecific monoclonal antibody effectively target carcinoembryonic antigen and a radiolabelled chelate for cancer therapy?
Conclusion
The humanised bispecific monoclonal antibody demonstrated high immunoreactivity and potential for use in two-phase radioimmunotherapy.
Supporting Evidence
- Three stable clones of bispecific monoclonal antibodies were identified from 730 isolated clones.
- The purification process resulted in 95% reactive bispecific monoclonal antibody.
- Immunoreactivity studies indicated that over 95% of the bispecific humanised monoclonal antibody was functionally active.
Takeaway
Scientists created a special type of antibody that can target cancer cells and deliver treatment without causing a strong reaction in the body.
Methodology
The antibody was produced by double transfection of BHK cells and purified using immunoaffinity chromatography.
Limitations
The yield of the bispecific antibody was lower than expected, and the purification process was complex.
Want to read the original?
Access the complete publication on the publisher's website